清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Cell membrane‐coated nanoparticles for the treatment of cancer

纳米医学 生物相容性 纳米技术 纳米载体 药物输送 癌细胞 材料科学 癌症 纳米颗粒 医学 内科学 冶金
作者
Nishta Krishnan,Ronnie H. Fang,Liangfang Zhang
出处
期刊:Clinical and translational medicine [Springer Science+Business Media]
卷期号:13 (6) 被引量:36
标识
DOI:10.1002/ctm2.1285
摘要

Over the last two decades, nanomedicine has rapidly grown as a field that utilizes nanoscale materials for biomedical applications. With their ability to improve control over the localization and release of therapeutic agents, nanocarriers offer a safer and more effective approach for addressing a wide range of diseases.1 Along these lines, cell membrane coating is an emerging technology that has been leveraged to significantly improve the functionality of nanoparticulate platforms (Figure 1).2 Cell membrane-coated nanoparticles (CNPs) possess many attributes that make them suitable for in vivo delivery applications, including improved biocompatibility, active targeting, increased stability, and reduced toxicity. As Fang et al. discussed recently in Nature Reviews Clinical Oncology, CNPs have become a promising tool for cancer treatment.3 One major advantage of employing CNPs for drug delivery is their inherent biocompatibility. The naturally derived outer layer on these biomimetic nanoparticles greatly reduces the toxicity and immunogenicity concerns that oftentimes limit the clinical application of traditional synthetic platforms. The cell membrane coating serves as a camouflage that enables CNPs to be recognized as 'self', thus allowing them to evade detection and clearance by the immune system. This ultimately prolongs in vivo residence time and enables the nanoparticles to carry out their designated functions more effectively. The membrane can be derived from any cell type, including, but not limited to, red blood cells, cancer cells, stem cells and immune cells.2 By selecting the appropriate cell source, CNPs can be designed to interact with specific disease substrates, allowing for more precise drug delivery and reduced off-target effects. For example, platelet membrane-coated nanoparticles that present P-selectin on their surface have been used to actively target breast cancer cells that express CD44.4 The addition of specific ligands onto the surface of CNPs can further boost their utility for drug delivery applications, and this has been accomplished using approaches such as chemical conjugation, lipid-based anchoring, genetic engineering and metabolic engineering.5 In contrast to traditional nanoengineering workflows, cell membrane coating offers a relatively streamlined approach for the development of disease-specific nanoformulations. When designing CNPs for targeted delivery applications, there is no need to undergo the time-consuming and labour-intensive processes of identifying and characterizing specific receptors on a cell or tissue of interest. Instead, researchers can directly take advantage of ligand–receptor interactions that have evolved over millions of years by utilizing membrane coatings that are derived from cells known to interact with a desired target. Furthermore, due to the fact that each CNP carries a diverse range of markers that can effectively interact with a variety of targets, a single formulation may be useful for multiple indications, which can also help to reduce the time and resources required for drug product development. In preclinical cancer treatment studies, CNPs have been evaluated for their ability to augment various therapeutic modalities, including drug delivery, phototherapy and immunotherapy.3 Long-circulating and targeted nanocarriers utilizing membrane coatings derived from red blood cells, platelets and cancer cells have proven to be excellent for the delivery of chemotherapeutics and other anticancer payloads. By enhancing localization to tumour sites, higher therapeutic efficacy can be achieved while concurrently reducing off-target effects that limit the maximum drug dosage patients can tolerate. Notably, CNPs fabricated using membrane derived from cancer cells have been widely utilized for cancer drug delivery applications due to their homotypic binding properties, which enables them to target tumours derived from the same source cell.6 This unique approach for cancer treatment may eventually be useful for the development of personalized formulations, in which CNPs are fabricated from a patient's own resected primary tumour material in order to prevent relapse and metastasis. While CNPs have been commonly used as carriers for cytotoxic drugs, researchers have more recently been exploring the use of such platforms to deliver photothermal and photosensitizing agents.7 After accumulation within tumours, these nanoscale phototherapeutics can be activated by light to induce local hyperthermia or to produce reactive oxygen species, thus resulting in tumour cell killing. Compared with other systemic treatment approaches, phototherapies provide an added layer of specificity, as the therapeutic action only occurs at the irradiated tumour region. Another area in which CNPs excel is cancer immunotherapy, as they can efficiently deliver immunostimulatory agents, serve as antigen sources or directly interface with immune cells to promote antitumour immunity.8 Nanoparticles coated with cancer cell membranes can be used to deliver tumour material along with potent adjuvants to immune cells, thereby promoting antigen presentation and the activation of antitumour immunity.9 In other cases, CNPs made using immune cell membranes can directly modulate the immune system to help overcome tumour immunosuppression.10 While CNPs have demonstrated considerable promise for anticancer applications, certain challenges remain for clinical translation. Importantly, production must be scaled up in order to meet the needs of human patients while adhering to strict quality requirements. Various synthetic nanoparticle platforms have already been approved for human use or are in late-stage clinical trials. For CNPs, much of the focus will likely be placed on the cell membrane derivation and coating processes, and existing industrial techniques such as microfluidization and tangential flow filtration can be adapted for cost-effective and high-yield production. Another consideration is the procurement of cell membrane for the preparation of CNPs. Many cell types are readily available, such as red blood cells, platelets and primary immune cells; in other cases, cell lines may be cultured in large quantities using bioreactors. All cell sources would need to be screened for transmissible diseases, and immunocompatibility with patients will be an important consideration. Finally, analytical assays need to be developed to ensure CNP quality at various stages during their manufacture. The integrity of key proteins, potency, physicochemical properties, stability and presence of microbial/viral contaminants are among some of the many parameters that will need to be evaluated. Overall, CNPs hold immense potential as a new class of anticancer therapeutics due to their many favourable attributes, such as high biocompatibility, specific targeting ability, streamlined development and broad applicability. Development on CNPs is rapidly advancing, and considerable preclinical research has helped to validate their utility for various drug delivery, phototherapy and immunotherapy applications. While much work still needs to be done, continued efforts by researchers will undoubtedly address the challenges required for clinical translation. Ultimately, it is envisioned that CNPs may become a mainstay in the clinic, helping to significantly improve the outcomes of cancer patients. Liangfang Zhang holds equity interests in Cellics Therapeutics and Cello Therapeutics. The remaining authors declare no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被科研通管家采纳,获得30
6秒前
7秒前
迷你的金鱼完成签到,获得积分10
18秒前
甜美的冬天完成签到,获得积分10
20秒前
玛卡巴卡爱吃饭完成签到 ,获得积分0
22秒前
金秋完成签到,获得积分0
24秒前
包容大地完成签到,获得积分10
56秒前
重要盼易完成签到,获得积分10
1分钟前
兴奋雅香完成签到,获得积分10
1分钟前
高高仙人掌完成签到,获得积分10
1分钟前
笨小孩完成签到,获得积分10
1分钟前
认真太阳完成签到,获得积分10
1分钟前
楚科研完成签到 ,获得积分10
1分钟前
爆米花的应助被My_magnum_opus采纳,获得10
1分钟前
fossick2010完成签到 ,获得积分10
1分钟前
chyang完成签到,获得积分10
2分钟前
2分钟前
2分钟前
Maestro_S的应助被科研通管家采纳,获得30
2分钟前
靓丽的初丹完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
机灵的月光完成签到,获得积分10
2分钟前
2分钟前
完美飞柏完成签到,获得积分10
2分钟前
开心的灭龙完成签到,获得积分10
2分钟前
xiaoze完成签到 ,获得积分10
2分钟前
李祺完成签到 ,获得积分10
2分钟前
瞿绝悟完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
ZLPY发布了新的文献求助30
2分钟前
顺利的访曼完成签到,获得积分10
3分钟前
3分钟前
虚心从蓉完成签到,获得积分10
3分钟前
麻团儿完成签到,获得积分10
3分钟前
3分钟前
冷酷冬卉完成签到,获得积分10
3分钟前
852的应助被TingtingGZ采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173198
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767332
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476688